呼吸器感染症治療薬市場：医薬品別、適応疾患別、流通チャネル別-2023-2030年の世界予測

呼吸器感染症治療薬の世界市場は、2023年に453億3,000万米ドル、CAGR 7.78%で大きく成長すると予測され、2030年には767億米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の呼吸器感染症治療薬市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.呼吸器感染症治療薬の世界市場規模および予測は？

2.予測期間中、世界の呼吸器感染症治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.呼吸器感染症治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.呼吸器感染症治療薬の世界市場における競争戦略は？

5.呼吸器感染症治療薬の世界市場における技術動向と規制の枠組みは？

6.呼吸器感染症治療薬の世界市場における主要ベンダーの市場シェアは？

7.呼吸器感染症治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 喘息や気道感染症の報告が増加
    • 変化するライフスタイルと高齢者人口
    • この分野でのジェネリック医薬品とバイオシミラーの開発の増加
  • 抑制要因
    • 季節の表示と点検
  • 機会
    • 医薬品の開発と商業化への投資
    • ドラッグデリバリーシステムの技術開発
  • 課題
    • 抗菌剤耐性の出現
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 呼吸器感染症治療薬市場薬物別

• 抗生物質
• 咳止め薬
• 鼻詰まり除去剤
• 非ステロイド性抗炎症薬

第7章 呼吸器感染症治療薬市場：疾患適応症別

• 下気道感染症
• 上部気道感染症

第8章 呼吸器感染症治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの呼吸器感染症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の呼吸器感染症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの呼吸器感染症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET RESEARCH PROCESS
• FIGURE 2. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2022 VS 2030
• FIGURE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2022 VS 2030 (%)
• FIGURE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
• FIGURE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET DYNAMICS
• FIGURE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 5. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NASAL DECONGESTANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 10. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 13. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 27. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. CANADA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. CHINA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. INDIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ITALY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. POLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 114. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. QATAR RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 144. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 145. RESPIRATORY TRACT INFECTION THERAPEUTIC MARKET LICENSE & PRICING

The Global Respiratory Tract Infection Therapeutic Market is forecasted to grow significantly, with a projected USD 45.33 billion in 2023 at a CAGR of 7.78% and expected to reach a staggering USD 76.70 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Respiratory Tract Infection Therapeutic Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Respiratory Tract Infection Therapeutic Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drugs, market is studied across Antibiotics, Cough Suppressants, Nasal Decongestants, and Non-Steroidal Anti-Inflammatory Drugs. The Non-Steroidal Anti-Inflammatory Drugs is projected to witness significant market share during forecast period.

Based on Disease Indication, market is studied across Lower Respiratory Tract Infection and Upper Respiratory Tract Infection. The Upper Respiratory Tract Infection is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Respiratory Tract Infection Therapeutic Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Respiratory Tract Infection Therapeutic Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Tract Infection Therapeutic Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Tract Infection Therapeutic Market?

4. What is the competitive strategic window for opportunities in the Global Respiratory Tract Infection Therapeutic Market?

5. What are the technology trends and regulatory frameworks in the Global Respiratory Tract Infection Therapeutic Market?

6. What is the market share of the leading vendors in the Global Respiratory Tract Infection Therapeutic Market?

7. What modes and strategic moves are considered suitable for entering the Global Respiratory Tract Infection Therapeutic Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Respiratory Tract Infection Therapeutic Market, by Drugs, 2022 vs 2030
• 4.3. Respiratory Tract Infection Therapeutic Market, by Disease Indication, 2022 vs 2030
• 4.4. Respiratory Tract Infection Therapeutic Market, by Distribution Channel, 2022 vs 2030
• 4.5. Respiratory Tract Infection Therapeutic Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased reports cases of asthma and respiratory tract infection
    • 5.1.1.2. Changing Lifestyle and geriatric population
    • 5.1.1.3. Increase development of generic drugs and biosimilars in the space
  • 5.1.2. Restraints
    • 5.1.2.1. Seasonal indications and inspections
  • 5.1.3. Opportunities
    • 5.1.3.1. Investment in drug development and commercialization
    • 5.1.3.2. Technology development in drug delivery systems
  • 5.1.4. Challenges
    • 5.1.4.1. Emergence of antimicrobial resistance
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Respiratory Tract Infection Therapeutic Market, by Drugs

• 6.1. Introduction
• 6.2. Antibiotics
• 6.3. Cough Suppressants
• 6.4. Nasal Decongestants
• 6.5. Non-Steroidal Anti-Inflammatory Drugs

7. Respiratory Tract Infection Therapeutic Market, by Disease Indication

• 7.1. Introduction
• 7.2. Lower Respiratory Tract Infection
• 7.3. Upper Respiratory Tract Infection

8. Respiratory Tract Infection Therapeutic Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Respiratory Tract Infection Therapeutic Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Respiratory Tract Infection Therapeutic Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Tract Infection Therapeutic Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing